Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doripenem vs Comparator in Hospital-Acquired Pneumonia
NCT00211003Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- May 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of doripenem in hospital-acquired pneumonia (HAP) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Clinical response rate at the early follow-up visit. Started May 2004; status: completed.
02
Drugs
doripenem
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT00211003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211003.